Company Profile
Hanx Biopharmaceuticals (Wuhan) provides the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer.
Its portfolio also includes HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours, HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma, and HX111, an ADC drug candidate to treat solid tumours.
It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044) Completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC)
The autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Incorporated in 2014, Hanx Biopharmaceuticals (Wuhan) is headquartered in Wuhan, China.